Noxafil

Mucormycosis, Coccidioidomycosis, Neutropenia + 11 more
Treatment
2 FDA approvals
20 Active Studies for Noxafil

What is Noxafil

PosaconazoleThe Generic name of this drug
Treatment SummaryPosaconazole is a type of antifungal medication used to treat serious infections caused by Candida and Aspergillus fungi in people with weakened immune systems.
Noxafilis the brand name
image of different drug pills on a surface
Noxafil Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Noxafil
Posaconazole
2006
25

Approved as Treatment by the FDA

Posaconazole, also known as Noxafil, is approved by the FDA for 2 uses including Invasive bronchopulmonary aspergillosis and Bronchopulmonary Aspergillosis .
Invasive bronchopulmonary aspergillosis
Bronchopulmonary Aspergillosis

Effectiveness

How Noxafil Affects PatientsPosaconazole is a type of antifungal medication. It is related to another drug, itraconazole, but has been modified to be more effective and work against a wider range of fungi. Posaconazole can either kill fungi or stop them from growing.
How Noxafil works in the bodyPosaconazole is an antifungal drug that works by blocking the production of a key part of fungal cells, called ergosterol. It does this by targeting a special enzyme in the cells called sterol 14α-demethylase. When this enzyme is blocked, the production of ergosterol is also blocked, leading to the death of the fungal cells.

When to interrupt dosage

The endorsed amount of Noxafil relies on the diagnosed disorder, like prophylaxis of Aspergillus contamination, HIV and Coccidioidomycosis. The dosage also depends on the technique of delivery (e.g. Intravenous or Solution - Intravenous) as specified in the accompanying table.
Condition
Dosage
Administration
Mucormycosis
, 100.0 mg, 40.0 mg/mL, 300.0 mg, 18.0 mg/mL, 30.0 mg/mL, 200.0 mg/mL
, Suspension, Oral, Suspension - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Intravenous, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Tablet, coated, Tablet, coated - Oral, Powder, for suspension, Powder, for suspension - Oral
Coccidioidomycosis
, 100.0 mg, 40.0 mg/mL, 300.0 mg, 18.0 mg/mL, 30.0 mg/mL, 200.0 mg/mL
, Suspension, Oral, Suspension - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Intravenous, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Tablet, coated, Tablet, coated - Oral, Powder, for suspension, Powder, for suspension - Oral
prophylaxis of Aspergillus infection
, 100.0 mg, 40.0 mg/mL, 300.0 mg, 18.0 mg/mL, 30.0 mg/mL, 200.0 mg/mL
, Suspension, Oral, Suspension - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Intravenous, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Tablet, coated, Tablet, coated - Oral, Powder, for suspension, Powder, for suspension - Oral
Neutropenia
, 100.0 mg, 40.0 mg/mL, 300.0 mg, 18.0 mg/mL, 30.0 mg/mL, 200.0 mg/mL
, Suspension, Oral, Suspension - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Intravenous, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Tablet, coated, Tablet, coated - Oral, Powder, for suspension, Powder, for suspension - Oral
Neuroaspergillosis
, 100.0 mg, 40.0 mg/mL, 300.0 mg, 18.0 mg/mL, 30.0 mg/mL, 200.0 mg/mL
, Suspension, Oral, Suspension - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Intravenous, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Tablet, coated, Tablet, coated - Oral, Powder, for suspension, Powder, for suspension - Oral
HIV
, 100.0 mg, 40.0 mg/mL, 300.0 mg, 18.0 mg/mL, 30.0 mg/mL, 200.0 mg/mL
, Suspension, Oral, Suspension - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Intravenous, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Tablet, coated, Tablet, coated - Oral, Powder, for suspension, Powder, for suspension - Oral
Cryptococcosis
, 100.0 mg, 40.0 mg/mL, 300.0 mg, 18.0 mg/mL, 30.0 mg/mL, 200.0 mg/mL
, Suspension, Oral, Suspension - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Intravenous, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Tablet, coated, Tablet, coated - Oral, Powder, for suspension, Powder, for suspension - Oral
prophylaxis of Candida Infections
, 100.0 mg, 40.0 mg/mL, 300.0 mg, 18.0 mg/mL, 30.0 mg/mL, 200.0 mg/mL
, Suspension, Oral, Suspension - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Intravenous, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Tablet, coated, Tablet, coated - Oral, Powder, for suspension, Powder, for suspension - Oral
Esophageal Candidiasis
, 100.0 mg, 40.0 mg/mL, 300.0 mg, 18.0 mg/mL, 30.0 mg/mL, 200.0 mg/mL
, Suspension, Oral, Suspension - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Intravenous, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Tablet, coated, Tablet, coated - Oral, Powder, for suspension, Powder, for suspension - Oral
Immunocompromised
, 100.0 mg, 40.0 mg/mL, 300.0 mg, 18.0 mg/mL, 30.0 mg/mL, 200.0 mg/mL
, Suspension, Oral, Suspension - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Intravenous, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Tablet, coated, Tablet, coated - Oral, Powder, for suspension, Powder, for suspension - Oral
Yeast Infection
, 100.0 mg, 40.0 mg/mL, 300.0 mg, 18.0 mg/mL, 30.0 mg/mL, 200.0 mg/mL
, Suspension, Oral, Suspension - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Intravenous, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Tablet, coated, Tablet, coated - Oral, Powder, for suspension, Powder, for suspension - Oral
Bronchopulmonary Aspergillosis
, 100.0 mg, 40.0 mg/mL, 300.0 mg, 18.0 mg/mL, 30.0 mg/mL, 200.0 mg/mL
, Suspension, Oral, Suspension - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Intravenous, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Tablet, coated, Tablet, coated - Oral, Powder, for suspension, Powder, for suspension - Oral
Oropharyngeal Candidiasis
, 100.0 mg, 40.0 mg/mL, 300.0 mg, 18.0 mg/mL, 30.0 mg/mL, 200.0 mg/mL
, Suspension, Oral, Suspension - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Intravenous, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Tablet, coated, Tablet, coated - Oral, Powder, for suspension, Powder, for suspension - Oral
Chronic Graft Versus Host Disease
, 100.0 mg, 40.0 mg/mL, 300.0 mg, 18.0 mg/mL, 30.0 mg/mL, 200.0 mg/mL
, Suspension, Oral, Suspension - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Intravenous, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Tablet, coated, Tablet, coated - Oral, Powder, for suspension, Powder, for suspension - Oral

Warnings

Noxafil Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Noxafil.
Common Noxafil Drug Interactions
Drug Name
Risk Level
Description
(R)-warfarin
Major
The metabolism of (R)-warfarin can be decreased when combined with Posaconazole.
(S)-Warfarin
Major
The metabolism of (S)-Warfarin can be decreased when combined with Posaconazole.
1,2-Benzodiazepine
Major
The metabolism of 1,2-Benzodiazepine can be decreased when combined with Posaconazole.
3,5-diiodothyropropionic acid
Major
The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Posaconazole.
5-androstenedione
Major
The metabolism of 5-androstenedione can be decreased when combined with Posaconazole.
Noxafil Toxicity & Overdose RiskDuring clinical trials, no negative side effects were seen from taking up to 1600 mg/day of posaconazole. There was one instance of an accidental overdose of 1200 mg twice a day for 3 days, but no harmful effects were reported.
image of a doctor in a lab doing drug, clinical research

Noxafil Novel Uses: Which Conditions Have a Clinical Trial Featuring Noxafil?

187 active clinical trials are examining the potential of Noxafil for prophylaxis of Aspergillus infection, Candida Infections and HIV.
Condition
Clinical Trials
Trial Phases
Immunocompromised
5 Actively Recruiting
Phase 3, Not Applicable, Phase 1
Bronchopulmonary Aspergillosis
0 Actively Recruiting
Neutropenia
6 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 4, Phase 3
Cryptococcosis
0 Actively Recruiting
Neuroaspergillosis
0 Actively Recruiting
Mucormycosis
0 Actively Recruiting
Coccidioidomycosis
0 Actively Recruiting
prophylaxis of Aspergillus infection
0 Actively Recruiting
prophylaxis of Candida Infections
0 Actively Recruiting
Yeast Infection
0 Actively Recruiting
Esophageal Candidiasis
0 Actively Recruiting
Oropharyngeal Candidiasis
0 Actively Recruiting
Chronic Graft Versus Host Disease
25 Actively Recruiting
Phase 4, Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1
HIV
132 Actively Recruiting
Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4, Early Phase 1

Noxafil Reviews: What are patients saying about Noxafil?

4Patient Review
1/25/2014
Noxafil for Treatment for Prevention of Disseminated Candidiasis
The only problem I had with this treatment is that it left me feeling cold all the time, even when other people said the water was just right. Otherwise, it did a great job of clearing up my infection.
3Patient Review
11/12/2009
Noxafil for Prevention of Invasive Pulmonary Aspergillosis
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about noxafil

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the generic for Noxafil?

"This is a delayed release tablet of the drug posaconazole, to be taken by mouth."

Answered by AI

How long do you take Noxafil?

"The standard dosage for adults is 5 mL for the first day, then 2.5 mL each day for 13 days."

Answered by AI

What is the drug Noxafil used for?

"Posaconazole is used as a prophylactic measure against fungal infections in immunocompromised patients, such as those undergoing chemotherapy. It is classified as an azole antifungal and works by suppressing the growth of fungi."

Answered by AI

Is Noxafil an antibiotic?

"Noxafil is an antifungal medicine used to treat or prevent fungal infections that can spread throughout your body. This medicine may be used in people with weak immune systems caused by certain treatments, such as chemotherapy or stem cell transplantation."

Answered by AI

Clinical Trials for Noxafil

Have you considered Noxafil clinical trials? We made a collection of clinical trials featuring Noxafil, we think they might fit your search criteria.
Have you considered Noxafil clinical trials? We made a collection of clinical trials featuring Noxafil, we think they might fit your search criteria.
Have you considered Noxafil clinical trials? We made a collection of clinical trials featuring Noxafil, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top